Galimedix, Inc. | Finanzwire

BRIEF

published on 03/12/2026 at 13:05, 5 days 5 hours ago

Galimedix Therapeutics Secures Milestone Payment in Partnership with Théa

Galimedix Therapeutics Théa Open Innovation GAL-101 Trials Ophthalmology Partnership Alzheimer's Advancement
PRESS RELEASE

published on 03/12/2026 at 13:00, 5 days 5 hours ago

Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation, advancing oral therapy for eye diseases and Alzheimer’s

Phase 1 Trial Alzheimer's Disease Galimedix Therapeutics Milestone Payment Ophthalmology Partnership
BRIEF

published on 03/05/2026 at 14:05, 12 days 4 hours ago

Galimedix Therapeutics to Showcase New Amyloid Beta Modulator at AD/PD 2026

Neurodegenerative Disorders Galimedix Therapeutics Pharmacokinetics Amyloid Beta AD/PD 2026 Conference
PRESS RELEASE

published on 03/05/2026 at 14:00, 12 days 4 hours ago

Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD™ 2026 Conference
Galimedix Therapeutics to present pre-clinical data on new oral amyloid beta modulator at AD/PD™ 2026 Conference, discussing GAL-201 prodrugs and improved pharmacokinetics

Galimedix Therapeutics Pre-clinical Data Pharmacokinetic Profile Oral Amyloid Beta Modulator AD/PD™ 2026 Conference
BRIEF

published on 12/04/2025 at 20:20, 3 months 12 days ago

Galimedix Therapeutics Reveals Promising Phase 1 Results for GAL-101

Phase 1 Results GAL-101 Alzheimer’s Treatment Blood-brain Barrier Phase 2 Planning
PRESS RELEASE

published on 12/04/2025 at 20:15, 3 months 12 days ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Galimedix Therapeutics presents compelling Phase 1 study results at CTAD 2025, demonstrating excellent safety and pharmacokinetics of GAL-101, planning Phase 2 study in Alzheimer's disease

Alzheimer's Disease Galimedix Therapeutics GAL-101 Phase 1 Study CTAD 2025
BRIEF

published on 09/12/2025 at 13:25, 6 months 5 days ago

Galimedix Advances Alzheimer's Research with Successful Phase 1 Completion

Clinical Trial Galimedix Therapeutics Alzheimer's Research Phase 1 Study GAL-101 Molecule
PRESS RELEASE

published on 09/12/2025 at 13:20, 6 months 5 days ago

Progress in clinical development for Alzheimer´s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modul
Galimedix successfully completes Phase 1 study with GAL-101, a small molecule targeting amyloid beta in Alzheimer's disease. Phase 2 trial planned

Alzheimer's Disease Phase 2 Trial GAL-101 Phase 1 Study Galimedix
BRIEF

published on 05/21/2025 at 14:05, 9 months 27 days ago

Galimedix's GAL-201 Shows Promise in Alzheimer's Treatment

GAL-201 Neuroinflammation Alzheimer’s Treatment Amyloid-beta Synaptic Damage
PRESS RELEASE

published on 05/21/2025 at 14:00, 9 months 27 days ago

Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease
Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease

GAL-201 Galimedix Therapeutics Alzheimer’s Disease International Journal Of Molecular Sciences Neuroprotective Therapy

Published on 03/17/2026 at 13:30, 5 hours 18 minutes ago

Hillcrest Energy Technologies Confirms ZVS PCS1000 Prototype on Track for June 2026
Published on 03/17/2026 at 13:30, 5 hours 18 minutes ago

Namibia Critical Metals Welcomes Toyota Tsusho as Strategic Partner in the Lofdal Heavy Rare Earths Project
Published on 03/17/2026 at 13:00, 5 hours 48 minutes ago

Avant Brands Announces Strategic Realignment of European Operations and Reclaims BLK MKT Brand Rights in Germany and Switzerland
Published on 03/17/2026 at 13:00, 5 hours 48 minutes ago

High-Resolution Airborne Survey Completed at Music Valley HREE Project
Published on 03/17/2026 at 12:30, 6 hours 18 minutes ago

Revival Gold Targets Underground Resource Growth With Drilling at Beartrack-Arnett Gold Project in Idaho

View all ACCESSWIRE

Published on 03/17/2026 at 18:07, 41 minutes ago

POS-Transaction in Own Shares
Published on 03/17/2026 at 17:58, 50 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/17/2026 at 17:45, 1 hour 3 minutes ago

FIGEAC AÉRO: THREE NEW WINS IN MEXICO
Published on 03/17/2026 at 15:30, 3 hours 18 minutes ago

Original-Research: Desert Gold Ventures Inc. (von GBC AG): Buy
Published on 03/17/2026 at 15:19, 3 hours 29 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group PLC

View all EQS

Published on 03/17/2026 at 07:00, 11 hours 48 minutes ago

Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 1 day ago

Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 1 day ago

Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 1 day ago

Reporting on share buyback transactions carried out between March 9 and March 13, 2026
Published on 03/16/2026 at 17:45, 1 day 1 hour ago

Weekly share buyback

View all LES ECHOS COMFI WIRE

News